PharmTech

What Sparsentan's FDA Approval Means for Rare Kidney Disease

Full FDA approval covers proteinuria reduction in FSGS without nephrotic syndrome, a defined clinical subset differentiated ...

FDA approval for Travere's drug expands reach to broader rare kidney disease patients

Travere Therapeutics Inc. TVTX shares are up on Tuesday following the announcement of full FDA approval for FILSPARI ...
BioSpace

Travere’s Filspari overcomes Phase 3 fail to become first drug for rare kidney disease

The FDA has greenlit Travere Therapeutics’ Filspari as the only available treatment for focal segmental glomerulosclerosis ...
pharmaphorum

Travere claims first FDA OK in rare kidney disease FSGS

Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare ...
Zacks Investment Research on MSN

TVTX stock soars on FDA nod for Filspari in second kidney indication

Travere Therapeutics TVTX shares surged 37.2% on Tuesday after the company announced that the FDA approved Filspari ...
The Lancet

How does it feel to live with kidney disease?

Kidney disease is a major global health issue with implications for the lives of millions of people and for the cost of health care. Yet there is surprisingly little public awareness about the ...